*Acinetobacter* species are important nosocomial and opportunistic pathogens that cause frequent outbreaks in intensive care units. Most strains involved in nosocomial infections are highly resistant to various antimicrobial agents and cause life-threatening illnesses. Carbapenems have been the drugs of choice to treat *Acinetobacter* infection because they are stable in response to extended-spectrum and AmpC β-lactamases. However, carbapenem-resistant *Acinetobacter* strains have been increasingly reported \[[@B1][@B2]\].

Carbapenemase production is the most critical mechanism of carbapenem resistance, and various carbapenemases, such as the Ambler class B metallo-β-lactamases (MBLs) of IMP, GIM, SIM, SPM, and VIM types and the Ambler class D carbapenemases of OXA-23, OXA-40, OXA-58, and OXA-143 types, have been reported in *Acinetobacter* species worldwide \[[@B3]\]. In addition, New Delhi MBL (NDM-1) has recently emerged as a key carbapenemase that compromises the efficiency of almost all β-lactams.

Although carbapenemase genes are widely disseminated among *Acinetobacter* species isolates, few data are available for *Acinetobacter* pittii isolates harboring carbapenemase. Clinically, *Acinetobacter baumannii* is the most commonly isolated species, but *A. pittii* isolates are also detected frequently and show resistance to various antimicrobial agents. In this study, we investigated carbapenemase genes in *A. pittii* isolates from a university hospital in Daejeon, Korea. In addition, multilocus sequence typing (MLST) was performed to analyze the relationship between carbapenemase types and *A. pittii* isolates harboring carbapenemases.

*A. pittii* isolates were collected at a university hospital laboratory in Daejeon, Korea, between January 2006 and December 2013. *A. pittii* was identified by using the Vitek 2 Automated Instrument ID System (bioMérieux; Marcy l\'Etoile, France) and by sequencing the partial *rpoB* housekeeping gene as described previously \[[@B4]\].

To investigate the presence of carbapenemases, we performed disk diffusion tests using 10-µg ertapenem disks (BD, Franklin Lakes, NJ, USA). All isolates with inhibition zone diameters of ≤21 mm on the ertapenem disks were subjected to carbapenemase detection. The minimum inhibitory concentrations (MICs) of *A. pittii* isolates for imipenem, meropenem, ceftazidime, and cefepime were determined with the Epsilon test (Etest; bioMérieux). The data were interpreted according to the criteria approved by CLSI \[[@B5]\]. *Escherichia coli* ATCC 25922 was used as a reference strain.

A total of 21 ertapenem-resistant *A. pittii* isolates were recovered from urine, sputum, or wound specimens. Most of these isolates (85.7%) were obtained from urine specimens ([Table 1](#T1){ref-type="table"}). The isolates were subjected to four multiplex PCR assays for the detection of carbapenemase genes. These assays were defined as multi-1, multi-2, multi-3, and multi-4 and were composed of specific primer sets \[[@B6][@B7][@B8]\]. Total DNA was obtained from each target strain by using a DNA purification kit (SolGent, Daejeon, Korea) in accordance with standard protocols. Each multiplex PCR was performed in a total volume of 25 µL with 50 ng total DNA, 2.5 µL 10× Taq buffer, 0.5 µL 10 mM dNTP mix, 20 pmol each primer, and 0.7 U Taq DNA polymerase (SolGent). PCR was performed in a GeneAmp PCR System 9600 thermal cycler (Perkin-Elmer Cetus Corp., Norwalk, CT, USA) with pre-denaturation of the reaction mixture at 95℃ for 5 min, followed by 35 cycles at 95℃ for 30 sec, 52℃ for 40 sec, and 72℃ for 30 sec, with a final extension at 72℃ for 5 min. The amplified products were separated via electrophoresis on 1.5% (w/v) agarose gels containing ethidium bromide and visualized with a BioDoc-14TM Imaging system (UVP, Cambridge, UK).

All positive isolates from the multiplex PCR were subjected to PCR assays with specific primers to identify carbapenemase genes \[[@B9]\]. NDM-1-positive *A. pittii* isolates were also subjected to PCR with previously described primers to analyze the surrounding structure of *bla*~NDM-1~ \[[@B10]\]. The amplicons were purified with a PCR purification kit (SolGent) and sequenced using a BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 3730XL DNA analyzer (PE Applied Biosystems). The various DNA sequences were confirmed with the Basic Local Alignment Search Tool (BLAST) paired alignment facility (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

An MLST scheme with seven housekeeping genes (*cpn60, fusA, gltA, pyrG, recA, rplB*, and *rpoB*) was used to determine the sequence types (STs) of *A. pittii* isolates \[[@B11]\]. Each ST number was assigned by comparing the allele sequences to those in the MLST databases (<http://www.pasteur.fr/mlst> and <http://pubmlst.org/abaumannii>).

All 21 consecutive *A. pittii* isolates resistant to ertapenem contained *bla*~IMP-1~ or *bla*~NDM-1~ ([Table 1](#T1){ref-type="table"}). However, other MBL genes and OXA-type carbapenemases were not found within the cohort.

Most of the ertapenem-resistant *A. pittii* isolates (90.5%) harbored *bla*~IMP-1~, and all of these isolates showed high resistance to imipenem (MICs ≥32 µg/mL) and meropenem (MICs ≥32 µg/mL). The frequency of these isolates was in accordance with that of previously reported *bla*~IMP-1~-containing *Acinetobacter* species isolated in Korea \[[@B12]\]. Our results indicate that *bla*~IMP-1~ is widely disseminated among ertapenem-resistant *A. pittii* isolates at the university hospital in Daejeon, Korea.

Interestingly, two ertapenem-resistant *A. pittii* isolates in this study contained *bla*~NDM-1~, which has been detected in *Enterobacteriaceae* clinical isolates in South Korea \[[@B13]\]. This study is the first to report an NDM-1-type MBL in *A. pittii* isolated in Korea. Because NDM-1 was first described in carbapenem-resistant *Klebsiella pneumoniae* and *Escherichia coli* isolates, this MBL has now been found in various *Enterobacteriaceae*, *Pseudomonas*, and *Acinetobacter* species \[[@B14]\]. Although NDM-1-producing isolates are usually resistant to carbapenems, the isolates harboring *bla*~NDM-1~ in our study were susceptible to imipenem and meropenem \[[@B10]\]. This result is similar to that of previous reports that some NDM-1 producers among *Enterobacteriaceae* and *Acinetobacter* showed lower MIC values to imipenem and meropenem \[[@B15][@B16]\]. Therefore, ertapenem rather than other carbapenems has been proposed for the detection of NDM producers \[[@B17]\].

Consequently, we analyzed the genetic environment of *bla*~NDM-1~ in the two *A. pittii* isolates and confirmed an approximately 3,500-bp nucleotide segment containing aminoglycoside resistance gene *aphA6* and transposase IS*Aba125* upstream and a truncated bleomycin resistance gene and *trpF* genes downstream of *bla*~NDM-1~. The segment detected in our study was identical to that reported in the previous study of *Acinetobacter* species \[[@B10]\], which reported that IS*Aba125* upstream of *bla*~NDM-1~ may be the main explanation for *bla*~NDM-1~ gene dissemination.

In this study, we performed MLST for epidemiological typing of ertapenem-resistant *A. pittii* isolates. The two bacterial isolates containing *bla*~NDM-1~ belonged to ST70 and ST207, which were different from the STs of the isolates harboring *bla*~IMP-1~ (ST63, ST119, ST396, and a novel ST). In previous studies, *bla*~NDM-1~ was identified in *A. pittii* isolates of ST63 in China \[[@B18]\], and NDM-1-producing strains isolated in Paraguay displayed ST320 and ST321 \[[@B19]\]. MLST profiles for four isolates containing *bla*~NDM-1~ identified in China differed from those described previously \[[@B10]\]. In addition, *A. pittii* isolates with ST63 and ST119 in Japan harbored *bla*~IMP-11~ and *bla*~IMP-19~, respectively \[[@B20]\]. Although the databases of MLST profiles for *A. pittii* are poor, our results suggest that ST was not directly related to MBL production in *A. pittii* isolates. Furthermore, the two strains harboring *bla*~NDM-1~ were all isolated in 2013, whereas the other strains were isolated before 2012. Our results suggest that *A. pittii* isolates harboring *bla*~NDM-1~ emerged only recently in Korea.

The emergence and dissemination of carbapenemase genes, including the NDM gene, in *Acinetobacter* species has become a major concern in the treatment of bacterial infections with antimicrobial agents. Early recognition and detection of carbapenemases are critical in controlling infection by clinical *Acinetobacter* isolates showing high resistance to carbapenems. On the basis of the findings that some carbapenemase producers can show susceptible phenotypes and that the NDM gene has a high propensity to disseminate, we suggest that the detection of carbapenem-producing isolates should extend to clinical isolates of carbapenem-susceptible *Acinetobacter* species in addition to carbapenem-resistant ones. In particular, additional tests are needed to detect carbapenemase producers with carbapenem susceptibility.
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###### Characteristics of *Acinetobacter pittii* isolates harboring *bla*~MBL~ genes

![](alm-35-531-i001)

  Isolate No.   Source   Year   ST    Allele profile^\*^     MBL gene       MIC (µg/mL)                    
  ------------- -------- ------ ----- ---------------------- -------------- ------------- ------- -------- --------
  601           Urine    2006   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  603           Urine    2006   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  605           Sputum   2006   119   36-20-38-16-38-18-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   128
  606           Urine    2006   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   24
  608           Urine    2006   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   48
  610           Urine    2006   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   48
  611           Wound    2006   396   60-21-46-10-20-18-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   48
  909           Urine    2009   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   32
  923           Sputum   2009   396   60-21-46-10-20-18-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   48
  931           Urine    2009   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 64    8
  952           Urine    2009   63    17-20-23-10-20-13-20   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  1114          Urine    2011   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  1115          Urine    2011   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  1147          Urine    2011   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  1148          Urine    2011   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  12200         Urine    2012   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  12247         Urine    2012   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  12273         Urine    2012   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   \> 256
  12280         Urine    2012   N     45-58-46-10-20-18-56   *bla*~IMP-1~   \> 32         \> 32   \> 256   48
  13049         Urine    2013   207   45-20-44-16-25-29-20   *bla*~NDM-1~   0.5           0.25    32       8
  13055         Urine    2013   70    23-20-23-16-25-18-20   *bla*~NDM-1~   1             0.25    \> 256   16

^\*^Indicates profiles of allele numbers attributed to each distinct allele sequence.

Abbreviations: IP, imipenem; MBL, metallo-β-lactamase; MIC, minimum inhibitory concentration; MP, meropenem; N, novel sequence type; PM, cefepime; ST, sequence type; TZ, ceftazidime.
